Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170817 · ClinicalTrials.gov registry record
Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 15
- Enrollment target
NCT03170817: Completed study, sponsored by Stanford University.
NCT03170817 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03170817 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.
Interventions
- DRUG Regadenoson
- DRUG N-13 ammonia
- DIAGNOSTIC_TEST Cardiac Perfusion Rest/Stress Digital PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2021-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170817
The ClinicalTrials.gov registry entry for NCT03170817 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regadenoson is the first listed.
NCT03170817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170817 about?
NCT03170817 is a clinical study titled "Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT". Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be pred...
What is the current status of trial NCT03170817?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2017-03-29. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT03170817?
The interventions under investigation include: Regadenoson (DRUG), N-13 ammonia (DRUG), Cardiac Perfusion Rest/Stress Digital PET/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03170817?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.